Sino Biopharmaceutical (OTCMKTS:SBMFF) Trading 4.9% Higher – Time to Buy?

Sino Biopharmaceutical Limited (OTCMKTS:SBMFF) rose 4.9% on Monday . The company traded as high as $0.45 and last traded at $0.44. Approximately 5,500 shares traded hands during trading, an increase of 153% from the average daily volume of 2,175 shares. The stock had previously closed at $0.42.

Sino Biopharmaceutical Trading Up 4.9 %

The company has a quick ratio of 1.07, a current ratio of 1.15 and a debt-to-equity ratio of 0.02. The firm’s fifty day moving average is $0.41 and its 200-day moving average is $0.42.

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.